10:01 AM EST - Resverlogix Corp. : Announced key data from its BETonMACE clinical trial in pre-specified stage 3 chronic kidney disease (CKD) patients. This data was presented in a virtual oral plenary session at the 57th ERA-EDTA Virtual Congress this morning by Dr. Kam Kalantar-Zadeh, MD, MPH, PhD, Professor and Chief, Division of Nephrology, Hypertension, and Kidney Transplantation, University of California Irvine, California. The presentation was titled, “Effects of the bet-inhibitor apabetalone on cardiovascular events in patients with type 2 diabetes mellitus and acute coronary syndrome, according to presence or absence of chronic kidney disease. A BETonMACE trial report.” Resverlogix Corp.
shares T.RVX are trading up $0.01 at $0.58.